Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Morphic Holding Inc
(NQ:
MORF
)
56.99
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Morphic Holding Inc
< Previous
1
2
3
4
5
Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
July 20, 2022
Upgrades
Via
Benzinga
Short Volatility Alert: Morphic Holding, Inc.
May 27, 2022
On Thursday, shares of Morphic Holding, Inc. (NASDAQ: MORF) experienced volatile short activity. After the activity, the stock price went up +4.69% to $22.53. The overall...
Via
Benzinga
Looking Into Morphic Holding's Return On Capital Employed
May 20, 2022
Benzinga Pro data, Morphic Holding (NASDAQ:MORF) reported Q1 sales of $2.38 million. Earnings fell to a loss of $31.48 million, resulting in a 47.11% decrease from last quarter.
Via
Benzinga
Morphic Holding: Q1 Earnings Insights
May 04, 2022
Morphic Holding (NASDAQ:MORF) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Morphic Holding
May 05, 2022
Over the past 3 months, 4 analysts have published their opinion on Morphic Holding (NASDAQ:MORF) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Wells Fargo Maintains Overweight Rating for Morphic Holding: Here's What You Need To Know
May 05, 2022
Wells Fargo has decided to maintain its Overweight rating of Morphic Holding (NASDAQ:MORF) and lower its price target from $81.00 to $79.00. Shares of Morphic Holding are trading down 3.76% over the...
Via
Benzinga
71 Biggest Movers From Yesterday
April 27, 2022
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (...
Via
Benzinga
Stocks Flounder As Wall Street Rotates Out Of Tech
April 26, 2022
Big Tech stocks are struggling ahead of several key earnings reports.
Via
Talk Markets
34 Stocks Moving In Tuesday's Mid-Day Session
April 26, 2022
Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday...
Via
Benzinga
CFO And COO Of Morphic Holding Trades $2.2M In Company Stock
October 18, 2021
Marc Schegerin, CFO And COO at Morphic Holding (NASDAQ:MORF), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A Form 4...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
The Past Week's Notable Insider Buys Include AppLovin, Cricut, Biotechs, And More
August 21, 2021
With earnings-reporting season all but over, many insiders are free once more to buy or sell shares. Here are a few of the most noteworthy insider purchases that were reported in the past week.
Via
Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
April 20, 2022
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
March 31, 2022
Upgrades
Via
Benzinga
The Past Week's Notable Insider Buys Included AppLovin, Cricut, Biotechs And More
August 21, 2021
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders were making return trips to the buy window...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
December 08, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...
Via
Benzinga
Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study
July 09, 2021
Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD). The data...
Via
Benzinga
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
July 03, 2021
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,...
Via
Talk Markets
Exposures
COVID-19
Product Safety
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
July 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...
Via
Benzinga
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
July 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...
Via
Benzinga
Topics
Product Recall
Exposures
COVID-19
Legal
Product Safety
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
July 03, 2021
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few...
Via
Benzinga
Exposures
Product Safety
Notable Insider Buys Of The Last Week: Bumble, Coty, Peloton Interactive, More
May 29, 2021
Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain or near all-time highs. Some return buyers were among the insiders...
Via
Benzinga
Is Morphic Holding a Buy?
April 14, 2021
This experimental biotech has more than tripled investors' money over the past 12 months.
Via
The Motley Fool
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.